Association of Hydroxyethyl Starch Administration With Mortality and Acute Kidney Injury in Critically Ill Patients Requiring Volume Resuscitation: A Systematic Review and Meta-analysis
Ryan Zarychanski,Ahmed M Abou-Setta,Alexis Turgeon,Brett L. Houston,Lauralyn McIntyre,John C. Marshall,Dean Fergusson +6 more
Reads0
Chats0
TLDR
In critically ill patients requiring acute volume resuscitation, use of hydroxyethyl starch compared with other resuscitation solutions was not associated with a decrease in mortality and clinical use ofHydroxyethyl starch for acuteVolume resuscitation is not warranted due to serious safety concerns.Abstract:
Importance Hydroxyethyl starch is commonly used for volume resuscitation yet has been associated with serious adverse events, including acute kidney injury and death. Clinical trials of hydroxyethyl starch are conflicting. Moreover, multiple trials from one investigator have been retracted because of scientific misconduct. Objectives To evaluate the association of hydroxyethyl starch use with mortality and acute kidney injury. Data Sources Randomized controlled trials from MEDLINE, EMBASE, CENTRAL, Global Health, HealthStar, Scopus, Web of Science, the International Clinical Trials Registry Platform (inception to October 2012), reference lists of relevant articles, and gray literature. Study Selection Two reviewers independently identified randomized controlled trials comparing hydroxyethyl starch with other resuscitation fluids in critically ill patients receiving acute volume resuscitation. Data Extraction Two reviewers independently extracted trial-level data including population characteristics, interventions, outcomes, and funding sources. Risk of bias was assessed using the risk of bias tool; the strength of evidence was adjudicated using the GRADE methodology. Results We included 38 eligible trials comparing hydroxyethyl starch to crystalloids, albumin, or gelatin. The majority of trials were categorized as having an unclear risk or high risk of bias. For the 10 880 patients in studies contributing mortality data, the risk ratio (RR) for death among patients randomized to receive hydroxyethyl starch was 1.07 (95% CI, 1.00 to 1.14; I 2 , 0%; absolute risk [AR], 1.20%; 95% CI, −0.26% to 2.66%). This summary effect measure included results from 7 trials performed by an investigator whose subsequent research had been retracted because of scientific misconduct. When we excluded these 7 trials that involved 590 patients, hydroxyethyl starch was found to be associated with increased mortality among 10 290 patients (RR, 1.09; 95% CI, 1.02 to 1.17; I 2 , 0%; AR, 1.51%; 95% CI, 0.02% to 3.00%), increased renal failure among 8725 patients (RR, 1.27; 95% CI, 1.09 to 1.47; I 2 , 26%; AR, 5.45%; 95% CI, 0.44% to 10.47%), and increased use of renal replacement therapy among 9258 patients (RR, 1.32; 95% CI, 1.15 to 1.50; I 2 , 0%; AR, 3.12%; 95% CI, 0.47% to 5.78%). Conclusion and Relevance In critically ill patients requiring acute volume resuscitation, use of hydroxyethyl starch compared with other resuscitation solutions was not associated with a decrease in mortality. Moreover, after exclusion of 7 trials performed by an investigator whose research has been retracted because of scientific misconduct, hydroxyethyl starch was associated with a significant increased risk of mortality and acute kidney injury. Clinical use of hydroxyethyl starch for acute volume resuscitation is not warranted due to serious safety concerns.read more
Citations
More filters
Journal ArticleDOI
Albumin Replacement in Patients with Severe Sepsis or Septic Shock
Pietro Caironi,Gianni Tognoni,Serge Masson,Roberto Fumagalli,Antonio Pesenti,Marilena Romero,Caterina Fanizza,Luisa Caspani,Stefano Faenza,Giacomo Grasselli,Gaetano Iapichino,Massimo Antonelli,Vieri Parrini,Gilberto Fiore,Roberto Latini,Luciano Gattinoni,Abstr Act +16 more
TL;DR: In patients with severe sepsis, albumin replacement in addition to crystalloids, as compared with crystalloids alone, did not improve the rate of survival at 28 and 90 days.
Journal ArticleDOI
KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury
Paul M. Palevsky,Kathleen D. Liu,Patrick D. Brophy,Lakhmir S. Chawla,Chirag R. Parikh,Charuhas V. Thakar,Ashita Tolwani,Sushrut S. Waikar,Steven D. Weisbord +8 more
TL;DR: A group of US experts in adult and pediatric AKI and critical care nephrology to review the recommendations and comment on their relevancy in the context of current US clinical practice and concerns concluded that there is insufficient evidence to support their widespread application to clinical care in the United States.
Journal ArticleDOI
Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children
Scott L. Weiss,Mark J. Peters,Waleed Alhazzani,Michael S. D. Agus,Heidi R. Flori,David Inwald,Simon Nadel,Luregn J. Schlapbach,Robert C. Tasker,Andrew C. Argent,Joe Brierley,Joseph Carcillo,Enitan D. Carrol,Christopher L. Carroll,Ira M. Cheifetz,Karen Choong,Jeffry J. Cies,Andrea T. Cruz,Daniele De Luca,Daniele De Luca,Akash Deep,Saul N. Faust,Claudio Flauzino De Oliveira,Mark W. Hall,Paul Ishimine,Etienne Javouhey,Koen F. M. Joosten,Poonam Joshi,Oliver Karam,Martin C. J. Kneyber,Joris Lemson,Graeme MacLaren,Nilesh M. Mehta,Morten Hylander Møller,Christopher J. L. Newth,Trung C. Nguyen,Akira Nishisaki,Mark E. Nunnally,Margaret M. Parker,Raina Paul,Adrienne G. Randolph,Suchitra Ranjit,Lewis H. Romer,Halden F. Scott,Lyvonne N Tume,Judy T. Verger,Judy T. Verger,Eric A. Williams,Joshua Wolf,Hector R. Wong,Jerry J. Zimmerman,Niranjan Kissoon,Pierre Tissieres,Pierre Tissieres +53 more
TL;DR: A large cohort of international experts was able to achieve consensus regarding many recommendations for the best care of children with sepsis, acknowledging that most aspects of care had relatively low quality of evidence resulting in the frequent issuance of weak recommendations.
Journal ArticleDOI
The systemic immune response to trauma: an overview of pathophysiology and treatment.
Janet M. Lord,Mark J. Midwinter,Yen-Fu Chen,Yen-Fu Chen,Antonio Belli,Karim Brohi,Elizabeth J. Kovacs,Leo Koenderman,Paul Kubes,Richard J. Lilford,Richard J. Lilford +10 more
TL;DR: The biological mechanisms and clinical implications of the cascade of events caused by large-scale trauma that leads to multiorgan failure and death, despite the stemming of blood loss are examined.
Journal ArticleDOI
Acute kidney injury—epidemiology, outcomes and economics
Oleksa G. Rewa,Sean M. Bagshaw +1 more
TL;DR: Survivors of AKI, particularly those who remain on renal replacement therapy, often have reduced quality of life and consume substantially greater health-care resources than the general population as a result of longer hospitalizations, unplanned intensive care unit admissions and rehospitalizations.
References
More filters
Journal Article
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
TL;DR: The QUOROM Statement (QUality Of Reporting Of Meta-analyses) as mentioned in this paper was developed to address the suboptimal reporting of systematic reviews and meta-analysis of randomized controlled trials.
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Related Papers (5)
Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis
Anders Perner,Nicolai Haase,Anne Berit Guttormsen,Anne Berit Guttormsen,Jyrki Tenhunen,Gudmundur Klemenzson,Anders Aneman,Kristian Rørbæk Madsen,Morten Hylander Møller,Jeanie M. Elkjær,Lone Musaeus Poulsen,Asger Bendtsen,Robert Winding,Morten Steensen,Pawel Berezowicz,Peter Søe-Jensen,Morten H. Bestle,Kristian Strand,Jørgen Wiis,Jonathan White,Klaus J. Thornberg,Lars Quist,Jonas B. Nielsen,Lasse H. Andersen,Lars Broksø Holst,Katrin Thormar,Anne Lene Kjældgaard,Maria Louise Fabritius,Frederik Mondrup,Frank Christian Pott,Thea Palsgaard Møller,Per Winkel,Jørn Wetterslev +32 more
Intensive insulin therapy and pentastarch resuscitation in severe sepsis.
Frank M. Brunkhorst,Christoph Engel,Frank Bloos,Andreas Meier-Hellmann,Max Ragaller,Norbert Weiler,Onnen Moerer,Matthias Gruendling,Michael Oppert,Stefan Grond,Derk Olthoff,Ulrich Jaschinski,Stefan John,Rolf Rossaint,Tobias Welte,Martin Schaefer,Peter M. Kern,Evelyn Kuhnt,Michael Kiehntopf,Christiane S. Hartog,Charles Natanson,Markus Loeffler,Konrad Reinhart +22 more